How can
we help?

Autologous

Autologous cell therapies are a key cog within the cell and gene therapy push. Cells from an individual patient are collected, manipulated ex vivo and then administered back into the patient. Such therapies have shown promise across a wide range of therapeutic areas. A challenge with autologous cell therapies is the patient-specific nature causing issues with scale-up to a commercial scale as separate batches are produced for each patient, along with the requirement of the patient being at the beginning and end of the process. Famicord can assist your autologous cell therapy pipeline by offering a scale-out service for autologous therapies, and with a network of laboratories across Europe, our proximity to patients is key in reducing supply chain complexity.

Click here to discuss your Autologous therapy requirements

Allogeneic

Allogeneic cell therapies offer a solution to many of the challenges seen in autologous cell therapies with scalability being much more achievable. The challenges associated with Allogeneic cell therapies are scaling up the manufacturing capacity to meet commercial demands. Famicord can assist in this scale-up process ensuring a robust and efficient process early on in the development program to meet commercial demands at a later stage. Our flexible nature will allow us to build a partnership with commercial success in mind from the start.

Click here to discuss your Allogeneic therapy requirements

Viral Vectors

Viral vectors are a key asset in gene therapies. An ability to deliver genetic material to the cell is a key to many soon to be therapies. With low efficiencies in many manufacturing processes our scientists have developed a process for lentiviral manufacturing regardless of scale. We have the capacity and capabilities to assist with process development and GMP manufacturing of Lentiviral vectors from our state-of-the-art facilities.

Click here to discuss your viral vector requirements

Gene Modification

Utilising other gene modification techniques. e.g. Crispr.